<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-13T04:42:08Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:11351/11120" metadataPrefix="didl">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:11351/11120</identifier><datestamp>2025-10-24T10:33:53Z</datestamp><setSpec>com_2072_378070</setSpec><setSpec>com_2072_378040</setSpec><setSpec>col_2072_378092</setSpec></header><metadata><d:DIDL xmlns:d="urn:mpeg:mpeg21:2002:02-DIDL-NS" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">
   <d:DIDLInfo>
      <dcterms:created xmlns:dcterms="http://purl.org/dc/terms/" xsi:schemaLocation="http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/dcterms.xsd">2025-10-24T10:33:53Z</dcterms:created>
   </d:DIDLInfo>
   <d:Item id="hdl_11351_11120">
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <dii:Identifier xmlns:dii="urn:mpeg:mpeg21:2002:01-DII-NS" xsi:schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:11351/11120</dii:Identifier>
         </d:Statement>
      </d:Descriptor>
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
               <dc:title>Angiotensin ii therapy in refractory septic shock: which patient can benefit most? A narrative review</dc:title>
               <dc:creator>Coloretti, Irene</dc:creator>
               <dc:creator>Genovese, Andrea</dc:creator>
               <dc:creator>Teixeira, Pedro J.</dc:creator>
               <dc:creator>Cherian, Anusha</dc:creator>
               <dc:creator>LANDONI, Giovanni</dc:creator>
               <dc:creator>Ferrer, Ricard</dc:creator>
               <dc:subject>Xoc sèptic - Tractament</dc:subject>
               <dc:subject>Hipotensió arterial</dc:subject>
               <dc:subject>DISEASES::Bacterial Infections and Mycoses::Infection::Sepsis::Shock, Septic</dc:subject>
               <dc:subject>Other subheadings::Other subheadings::Other subheadings::/drug therapy</dc:subject>
               <dc:subject>DISEASES::Cardiovascular Diseases::Vascular Diseases::Hypotension</dc:subject>
               <dc:subject>ENFERMEDADES::infecciones bacterianas y micosis::infección::sepsis::choque séptico</dc:subject>
               <dc:subject>Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia</dc:subject>
               <dc:subject>ENFERMEDADES::enfermedades cardiovasculares::enfermedades vasculares::hipotensión</dc:subject>
               <dc:description>Angiotensina II; Shock sèptic; Vasopressors</dc:description>
               <dc:description>Angiotensin II; Septic shock; Vasopressors</dc:description>
               <dc:description>Angiotensina II; Shock séptico; Vasopresores</dc:description>
               <dc:description>Patients with septic shock who experience refractory hypotension despite adequate fluid resuscitation and high-dose noradrenaline have high mortality rates. To improve outcomes, evidence-based guidelines recommend starting a second vasopressor, such as vasopressin, if noradrenaline doses exceed 0.5 µg/kg/min. Recently, promising results have been observed in treating refractory hypotension with angiotensin II, which has been shown to increase mean arterial pressure and has been associated with improved outcomes. This narrative review aims to provide an overview of the pathophysiology of the renin-angiotensin system and the role of endogenous angiotensin II in vasodilatory shock with a focus on how angiotensin II treatment impacts clinical outcomes and on identifying the population that may benefit most from its use.</dc:description>
               <dc:date>2025-10-24T10:33:53Z</dc:date>
               <dc:date>2025-10-24T10:33:53Z</dc:date>
               <dc:date>2024-02-26T12:42:51Z</dc:date>
               <dc:date>2024-02-26T12:42:51Z</dc:date>
               <dc:date>2024-02-21</dc:date>
               <dc:type>info:eu-repo/semantics/article</dc:type>
               <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
               <dc:identifier>http://hdl.handle.net/11351/11120</dc:identifier>
               <dc:relation>Journal of Anesthesia, Analgesia and Critical Care;4</dc:relation>
               <dc:relation>https://doi.org/10.1186/s44158-024-00150-w</dc:relation>
               <dc:rights>Attribution 4.0 International</dc:rights>
               <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
               <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
               <dc:publisher>BMC</dc:publisher>
               <dc:source>Scientia</dc:source>
            </oai_dc:dc>
         </d:Statement>
      </d:Descriptor>
   </d:Item>
</d:DIDL></metadata></record></GetRecord></OAI-PMH>